Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 14:2:98.
doi: 10.3389/fonc.2012.00098. eCollection 2012.

The strategy for enhancing temozolomide against malignant glioma

Affiliations

The strategy for enhancing temozolomide against malignant glioma

Mitsutoshi Nakada et al. Front Oncol. .

Abstract

A combined therapy of the alkylating agent temozolomide (TMZ) and radiotherapy is standard treatment, and it improves the survival of patients with newly diagnosed glioblastoma (GBM). The DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) removes the most cytotoxic lesions generated by TMZ, O(6)-methylguanine, establishing MGMT as one of the most important DNA repair mechanisms of TMZ-induced DNA damage. Thus, the expression of MGMT, its activity, and its promoter methylation status are associated with the response of GBM to TMZ, confirming that MGMT promotes clinical resistance to TMZ. Previous studies have shown that a variety of drugs such as interferon-β (IFN-β), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. In this review, we describe drugs and promising molecules that influence the responsiveness of GBM to TMZ and discuss their putative mechanism of action. In MGMT-positive GBMs, drugs that modulate MGMT activity could enhance the therapeutic activity of TMZ. Thus, administration of these drugs as an adjunct to TMZ chemotherapy may have clinical applications in patients with malignant gliomas to improve the outcome.

Keywords: MGMT; chemosensitivity; glioma; interferon-β; levetiracetam; resveratrol; temozolomide; valproic acid.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Levetiracetam increases HDAC1 transcription and recruit HDAC1/mSin3A corepressor, which binds MGMT promoter region intermediated by p53. This complex of three components inhibits MGMT transcription.
Figure 2
Figure 2
Two pathways of methylated DNA repair. TMZ generates a spectrum of DNA lesions including O6-methylguanine, N3-methyladenine, and N7-methylguanine. MGMT eliminates directly the methyl group from O6-methylguanine, whereas BER pathway includes multistep reaction by DNA glycosylase (APNG or MPG), endonuclease, polymerase, and DNA ligase. DNA glycosylase recognizes and removes the damaged bases. The abasic site is then hydrolyzed by endonuclease, resulting in the incision of the damaged DNA strand. Polymerase inserts a single nucleotide and DNA ligase completes the repair process. PARP, one of the polymerases of BER, catalyzes the transfer of ADP-ribose units from NAD+ to target proteins including PARP itself. Therefore, inhibition or hyperactivation of PARP leads to accumulation of broken DNA or NAD+ depletion respectively, consequently inducing cell death.

Similar articles

Cited by

References

    1. Agnihotri S., Gajadhar A. S., Ternamian C., Gorlia T., Diefes K. L., Mischel P. S., Kelly J., McGown G., Thorncroft M., Carlson B. L., Sarkaria J. N., Margison G. P., Aldape K., Hawkins C., Hegi M., Guha A. (2012). Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J. Clin. Invest. 122, 253–266 10.1172/JCI59334 - DOI - PMC - PubMed
    1. Agnihotri S., Wolf A., Munoz D. M., Smith C. J., Gajadhar A., Restrepo A., Clarke I. D., Fuller G. N., Kesari S., Dirks P. B., McGlade C. J., Stanford W. L., Aldape K., Mischel P. S., Hawkins C., Guha A. (2011). A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J. Exp. Med. 208, 689–702 10.1084/jem.20102099 - DOI - PMC - PubMed
    1. Agnihotri S., Wolf A., Picard D., Hawkins C., Guha A. (2009). GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system. Oncogene 28, 3033–3046 10.1038/onc.2009.159 - DOI - PubMed
    1. Barker C. A., Burgan W. E., Carter D. J., Cerna D., Gius D., Hollingshead M. G., Camphausen K., Tofilon P. J. (2006). in vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhi-bitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin. Cancer Res. 12, 2912–2918 10.1158/1078-0432.CCR-05-2860 - DOI - PubMed
    1. Bobola M. S., Tseng S. H., Blank A., Berger M. S., Silber J. R. (1996). Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res. 2, 735–741 - PubMed